Seegene INC.
Myung Kim is an accomplished finance professional with extensive experience in consolidation and external reporting. Currently serving as Sr. Manager at Seegene INC. since December 2021, Myung Kim leads the consolidation of financial statements for multiple subsidiaries under IFRS and US GAAP, conducts financial planning and analysis for joint ventures and mergers, and oversees internal controls and ERP systems. Prior to this role, Myung Kim held positions at Hawaiian Electric Company as Lead of Accounting Research & Reporting, where responsibilities included managing SEC filings, and at Deloitte as an Audit Manager, focusing on audits for SEC registrants. Myung Kim began the career as an Audit Senior at Sato & Yamamoto LLP, working on audit engagements across various industries and assisting with tax filings. Myung Kim holds a degree from the University of Hawaii at Manoa.
This person is not in any teams
Seegene INC.
1 followers
[INTRODUCING OUR COMPANY] The people of Seegene are on a purposeful mission to improve the world we live in. We aim to improve the quality of life for everyone globally by bringing molecular diagnostics to the masses. Molecular diagnostics is the most effective method to accurately diagnose ailments and is also the best way to diagnose them early which is when you can make the most difference in the recovery treatment. With industry-leading IP in molecular diagnostics reagent assays, we are dedicated to leveraging our unique technologies to increase our product portfolio, expand our market coverage, and lowering the total cost to serve our customers so that molecular diagnostics become a part of the fabric of everyone’s life and thus, improving the quality of life for everyone in the world. [OUR HISTORY AND OUR FUTURE] Since our founding in 2000, we have been steadfastly focused on molecular diagnostics. Currently, our product portfolio consists of over 250 molecular diagnostics reagent kits as well as a wide range of instruments and consumables that are sold globally. Testament to our expertise, when the pandemic started, Seegene was one of the first companies in the world to provide testing kits that were crucial in the fight against COVID. Today, we are a company with revenue of over $1 billion dollars and 65% gross margins. With 8 overseas entities, we generate a majority of our revenue outside of Korea. In keeping with our spirit of innovation and making a difference in the world, there are many exciting innovations being worked on at Seegene which will make it easier for the world to access the benefits of molecular diagnostics. We are transforming our business from a discrete reagent assay and instruments business to a platform business that will create new markets for molecular diagnostics and improve the quality of life for everyone. We hope that you will join us in our mission to make a meaningful difference in the world.